Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Increases By 30.0%

Definitive Healthcare Corp. (NASDAQ:DH) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,770,000 shares, a growth of 30.0% from the February 13th total of 2,130,000 shares. Based on an average daily trading volume, of 823,600 shares, the days-to-cover ratio is currently 3.4 days. Currently, 6.8% of the company’s shares are sold short.

Institutional Trading of Definitive Healthcare

Several large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its stake in shares of Definitive Healthcare by 3,652.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company’s stock worth $29,000 after buying an additional 6,794 shares in the last quarter. Bayesian Capital Management LP acquired a new position in shares of Definitive Healthcare in the 4th quarter worth approximately $41,000. Point72 DIFC Ltd raised its holdings in shares of Definitive Healthcare by 759.9% in the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after purchasing an additional 8,215 shares in the last quarter. Ieq Capital LLC acquired a new stake in Definitive Healthcare during the fourth quarter valued at approximately $51,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Definitive Healthcare during the fourth quarter worth approximately $54,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DH has been the subject of several research analyst reports. The Goldman Sachs Group dropped their price target on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Stephens started coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target on the stock. Finally, Barclays dropped their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.35.

Definitive Healthcare Stock Performance

DH traded up $0.11 during trading on Tuesday, reaching $2.78. 878,514 shares of the company were exchanged, compared to its average volume of 746,671. Definitive Healthcare has a 52 week low of $2.55 and a 52 week high of $8.35. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $4.31 and a 200 day moving average of $4.36. The stock has a market cap of $313.33 million, a P/E ratio of -0.90, a PEG ratio of 4.06 and a beta of 1.51.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The firm had revenue of $62.29 million during the quarter, compared to the consensus estimate of $60.60 million. On average, sell-side analysts forecast that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.